[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Kuratate S, Inoue S, Chikakiyo M, Kaneda Y, Harino Y, Hirose T, Yagi T, Saitoh S, Sumitomo M, Fujino R, Satake N: Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case. J Med Invest; 2010 Aug;57(3-4):338-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case.
  • A 74-years old man was referred to our hospital for treatment of a rectal mass.
  • Colonoscopy revealed villous tumor covering all the lower rectal lumen.
  • Rectosigmoidectomy with lymph node dissection was performed with the diagnosis of rectal cancer that metastasized to the liver.
  • Histological and immuno- histochemical features showed coexistent poorly-differentiated small cell neuroendocrine cell (NEC) carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma.
  • However the chemotherapy with FOLFOX and Bevacizumab was performed postoperatively, the patient died in cancer 3 months after surgery.
  • Rectal poorly-differentiated NEC carcinomas are thought to be a tumor with a high malignant potential.
  • They would be evaluated, and effective multimodal therapy for NEC carcinomas should be established.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiography. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847536.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Chintamani, Singhal V, Bansal A, Bhatnagar D, Saxena S: Isolated colostomy site recurrence in rectal cancer-two cases with review of literature. World J Surg Oncol; 2007;5:52
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated colostomy site recurrence in rectal cancer-two cases with review of literature.
  • Both patients had received adjuvant chemotherapy following surgery.
  • CASE PRESENTATION: First case was a 30-year-old male that had reported with large bowel obstruction due to an obstructing ulcero-proliferative growth (poorly differentiated adenocarcinoma) at the colostomy site after abdomino-perineal resection, performed for low rectal cancer six years previously.
  • Second case was a 47-year-old male that presented with acute large bowel obstruction due to an annular growth (well differentiated adenocarcinoma) in the upper rectum.
  • Five years following closure of colostomy, he presented with two parietal masses at the previous colostomy site scar, which, on fine needle aspiration cytology were found to be well-differentiated adenocarcinomas of colorectal type.
  • CONCLUSIONS: Colostomy site/scar recurrence of rectal carcinoma is rare and could be due to various etiological factors, although the exact causative mechanism is not known.
  • [MeSH-major] Adenocarcinoma / pathology. Colostomy / adverse effects. Neoplasms, Second Primary / pathology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2002;37(5):387-90 [12051539.001]
  • [Cites] J Postgrad Med. 2003 Apr-Jun;49(2):157-8 [12867694.001]
  • [Cites] Gastroenterology. 1958 Jan;34(1):85-98 [13501357.001]
  • [Cites] Cancer. 1974 Jun;33(6):1630-4 [4834157.001]
  • [Cites] Dis Colon Rectum. 1983 Jan;26(1):50-2 [6822162.001]
  • [Cites] Dis Colon Rectum. 1966 Nov-Dec;9(6):441-6 [5926156.001]
  • (PMID = 17567928.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  • [Other-IDs] NLM/ PMC1876234
  • [General-notes] NLM/ Original DateCompleted: 20070730
  •  go-up   go-down


3. Fukuda M, Takashima H, Fuse H, Hirano S: [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report]. Hinyokika Kiyo; 2002 Aug;48(8):499-502
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
  • Prostatic cancer was suspected on digital rectal examination and magnetic resonance imaging.
  • Histological examination of transrectal prostatic sextant biopsy revealed well differentiated adenocarcinoma of prostate.
  • Abdominal computed tomography-scan, gastro-intestinal tract examination and bone scintigraphy demonstrated no other primary lesions or distant metastases.
  • Under the diagnosis of prostatic cancer with multiple pulmonary metastasis, we performed total androgen blockade (TAB) consisting of luteinizing hormone releasing hormone agonist and flutamide following dietylstilbestrol (DES) intravenous injection therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Androgen Antagonists / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Gonadotropin-Releasing Hormone / agonists. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Diethylstilbestrol / administration & dosage. Drug Administration Schedule. Flutamide / administration & dosage. Goserelin / administration & dosage. Humans. Male. Prostate-Specific Antigen / blood. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12243078.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone; 731DCA35BT / Diethylstilbestrol; 76W6J0943E / Flutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 26
  •  go-up   go-down


Advertisement
4. Shibata N, Eto TA, Hotokezaka M, Iwamura T, Chijiiwa K: [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1159-62
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
  • A 43-year-old woman who complained of abdominal fullness, appetite loss, and constipation was diagnosed as unresectable advanced schirrhous gastric cancer with left supra-clavicular lymph node metastases, massive ascites, rectal stenosis, and bilateral hydronephrosis due to peritoneal metastases.
  • The biopsy specimen showed a poorly differentiated adenocarcinoma with signet-ring cells.
  • After placement of the bilateral ureteral stents, she was treated with combined chemotherapy of biweekly paclitaxel (120 mg/m2, day 1, day 15) and TS-1 (80 mg/day, days 1-14 with 2-weeks rest).
  • Subjective symptoms were relieved after one course of the chemotherapy.
  • After 3 courses, computed tomography showed markedly reduced supra-clavicular lymph node metastases and no ascites.
  • Radiographic and endoscopic examinations also demonstrated remarkable improvements in compliance of the gastric and rectal walls.
  • After the first course, the treatment was continued on an outpatient basis.
  • There were no adverse effects over grade 2 throughout six courses of the chemotherapy.
  • The biweekly paclitaxel and TS-1 chemotherapy may well be an effective treatment for advanced schirrhous gastric cancer with carcinomatous peritonitis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites. Constriction, Pathologic. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Peritonitis / etiology. Pyridines / administration & dosage. Rectal Diseases / etiology. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121920.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Mendenhall WM, Rout WR, Zlotecki RA, Mitchell SE, Marsh RD, Copeland EM 3rd: Conservative treatment of rectal adenocarcinoma. Hematol Oncol Clin North Am; 2001 Apr;15(2):303-19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment of rectal adenocarcinoma.
  • Endocavitary radiotherapy and transrectal excision are highly effective treatments for properly selected patients with favorable early-stage rectal adenocarcinoma.
  • The likelihood of local control and survival after treatment with either modality is similar, and differences among various series probably reflect selection.
  • Suitable candidates for endocavitary radiotherapy or wide local excision are patients whose tumors are 3 cm or less in diameter, well-to-moderately differentiated, exophytic, mobile, limited to the submucosa on transrectal ultrasound, and within 10 cm of the anal verge.
  • The advantages of endocavitary irradiation are (1) it is an outpatient procedure, (2) it does not require anesthesia, and (3) it is less expensive than transrectal excision.
  • A disadvantage of wide local excision is that some patients who would be suitable for a local procedure alone must be subjected to a course of external-beam radiotherapy when they are found to have equivocal or positive margins.
  • Patients who should receive postoperative irradiation have tumors that exhibit one or more of the following characteristics: size greater than 3 cm in diameter, poorly differentiated, invasion of the muscularis propria, endothelial-lined space invasion, fragmented resection, equivocal or positive margins, or perineural invasion.
  • Patients thought to have transmural invasion before treatment are probably best treated with preoperative chemoradiation combined with major surgery, although a subset of patients can be downstaged and rendered suitable for a wide local excision.
  • [MeSH-major] Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11370495.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


6. Sadahiro S, Suzuki T, Maeda Y, Tanaka Y, Nakamura T, Saguchi T, Yasuda S, Makuuchi H, Murayama C, Ohizumi Y: Predictors of tumor downsizing and regression with preoperative radiotherapy alone and with concomitant tegafur/uracil (UFT) for resectable advanced rectal adenocarcinoma. Hepatogastroenterology; 2007 Jun;54(76):1107-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of tumor downsizing and regression with preoperative radiotherapy alone and with concomitant tegafur/uracil (UFT) for resectable advanced rectal adenocarcinoma.
  • This study attempts to evaluate retrospectively the significance of apoptosis-related and proliferative indexes in biopsy specimens obtained before treatment as predictors of sensitivity to RT or to CRT for locally advanced rectal adenocarcinoma.
  • METHODOLOGY: The subjects were 96 patients with clinical T3-4/Nx/M0 adenocarcinoma of the middle third or lower third of the rectum.
  • Sixty-one patients were treated with preoperative RT alone (20 Gy in 10 fractions) [RT group] during 1991-1998, and 35 patients received concurrent oral tegafur/uracil (UFT) [CRT group] since 1999.
  • Radical surgery including TME and pelvic nerve preservation with 15 Gy of intraoperative RT was performed two weeks after completion of the preoperative radiation.
  • RESULTS: AI-positivity, p53-negativity, p21-positivity and well differentiated adenocarcinoma were predictors of high sensitivity in RT group, whereas AI-positivity alone was the predictor in CRT group.
  • The addition of UFT to RT increased sensitivity in patients with p53-positivity, p21-negativity and moderately differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / analysis. Drug Resistance, Neoplasm. Radiation Tolerance. Rectal Neoplasms / therapy
  • [MeSH-minor] Aged. Apoptosis. Female. Humans. Male. Middle Aged. Preoperative Care. Prognosis. Tegafur / administration & dosage. Treatment Outcome. Uracil / administration & dosage

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629049.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


7. Mendenhall WM, Zlotecki RA, Snead FE, George TJ Jr, Marsh RD, Mendenhall CM, Rout WR: Radiotherapy in the treatment of resectable rectal adenocarcinoma. Am J Clin Oncol; 2009 Dec;32(6):629-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy in the treatment of resectable rectal adenocarcinoma.
  • The goal of treatment is to cure whereas maintaining sphincter function and minimizing toxicity.
  • Although the mainstay of the treatment is surgery, radiotherapy (RT) is used in a substantial proportion of patients depending on the location and extent of the tumor.
  • The aim of this article is to discuss the role of RT in patients with resectable rectal adenocarcinoma.
  • Results show that patients with T1N0 exophytic, well to moderately differentiated, mobile tumors < or = 3 cm in diameter may be treated with either transanal excision or endocavitary RT.
  • The advantages of endocavitary RT are that it is an outpatient procedure requiring, at most, local anesthesia and is suitable for elderly, infirm patients.
  • The disadvantage is that few of these treatment units are available.
  • The addition of concomitant chemotherapy probably enhances downstaging and may improve the likelihood of sphincter preservation.
  • Patients with T3 and/or N1 rectal cancers have a relatively high probability of local-regional recurrence after surgery alone.
  • Preoperative RT and postoperative RT combined with adjuvant chemotherapy have been shown to significantly reduce the risk of local-regional recurrence and improve survival.
  • Whether preoperative RT alone or combined with chemotherapy is more efficacious than postoperative chemoradiation remains unclear.
  • Depending on tumor location and extent, adjuvant RT may improve the probability of local-regional control and survival for patients with locally advanced rectal adenocarcinomas.
  • [MeSH-major] Rectal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593081.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


8. Nikkuni K, Nagahashi M, Makino S, Nishimura A, Kawachi Y, Shimizu T: [A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2004 Oct;31(10):1591-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy].
  • We have experienced successful treatment of a multiple hepatic metastasis of rectal cancer with combination chemotherapy.
  • The patient is a 57-year-old male with bowel obstruction accompanied by rectal cancer (SE, N3, P1, H3, M (-) stage IV) who underwent a Hartmann operation with D3 lymph node dissection on July 6, 2000.
  • The histopathological findings revealed a well-differentiated adenocarcinoma (se, INFbeta, n3, ly2, v2, p1).
  • From the 11th postoperative day, combination chemotherapy using 5-FU 750 mg/day and LV 300 mg/day was performed once a week.
  • When he underwent 5 combination chemotherapy treatments, adverse effects of grade 3 occurred, and the serum CEA level rose rapidly.
  • We changed his regimen at that time.
  • He underwent 2 courses of combination chemotherapy with 5-FU 500 mg/day and CDDP 10 mg/day for 5 days.
  • Additional courses of combination chemotherapy with 5-FU 500 mg/day, LV 25 mg/day and CDDP 10 mg/day were performed weekly in the outpatient department.
  • The treatment was effective, and a complete response (CR) was noted 4 months after the chemotherapy.
  • The same combination chemotherapy was performed biweekly for one year after CR.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15508457.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Matsushita D, Kitazono M, Baba K, Ishigami S, Shinchi H, Ueno S, Ogawa H, Natsugoe S: [A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy]. Gan To Kagaku Ryoho; 2010 Jan;37(1):173-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].
  • Colonoscopy detected rectal cancer and sigmoid al polyps.
  • The biopsy results suggested that the rectal lesion was well- to moderately-differentiated adenocarcinoma and the sigmoidal polyp contained well -differentiated adenocarcinoma.
  • We judged the case to be inoperable and decided to start systemic chemotherapy (FOLFOX4).
  • After treatment with chemotherapy, the tumor shrank and metastatic lesions disappeared.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087057.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Noura S, Ohue M, Murata K, Kameyama M, Kishi K, Takachi K, Eguchi H, Yamada T, Miyashiro I, Yano M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S: [A case of high-dose rate interstitial brachytherapy for locally recurrent rectal cancer]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1801-3
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of high-dose rate interstitial brachytherapy for locally recurrent rectal cancer].
  • The patient was a 55-year-old female who underwent an abdomino-perineal resection for advanced lower rectal cancer.
  • The tumor was a well differentiated adenocarcinoma, type 2 in the Japanese classification of colorectal carcinoma, and was measured 2.3 cm in size.
  • She received adjuvant chemotherapy with 5'-DFUR.
  • After 13 months from the surgery, the patient developed a hip pain.
  • Biopsy from the tumor revealed adenocarcinoma.
  • Chemotherapy with CPT-11 (230 mg/body) and 5'-DFUR (800 mg/body) was administered for 2 cycles.
  • Because the tumor was enlarged, high-dose rate interstitial brachytherapy was given to the recurrent site at a total dose of 54 Gy/9 fractions/5 days.
  • Hence, high dose rate interstitial brachytherapy appears to be effective for locally recurrent rectal cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Rectal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212112.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


11. Kanoh T, Ohnishi T, Danno K, Watanabe A, Nakamura H, Tsukao Y, Inatome J, Kim C, Kagara N, Taniguchi H, Kimura Y, Tono T, Nakano Y, Monden T, Imaoka S: [A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2611-3
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy].
  • We report a case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy.
  • A colonoscopy revealed primary rectal cancer.
  • The histological diagnosis was well to moderately differentiated adenocarcinoma.
  • A computed tomography showed metastases to pararectal, both inguinal lymph nodes and right external iliac.
  • After a ileostomy construction was done, he was treated with intensity modulated radiotherapy (a total 50.4 Gy) and chemotherapy with FOLFOX.
  • Nine months after radiation therapy, however, multiple lung and liver metastases were observed by a computed tomography, which were treated by systemic chemotherapy with FOLFOX and bevacizumab.
  • The primary tumor and metastases to lymph nodes are still controlled well for 2 years after the initial chemoradiotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Lymphatic Metastasis. Rectal Neoplasms / therapy
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Combined Modality Therapy. Fluorouracil / therapeutic use. Humans. Ileostomy. Inguinal Canal. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / therapeutic use. Radiotherapy, Intensity-Modulated

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224655.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


12. Franceschi F, Fini L, Manno A, Carloni E, Zocco MA, Di Caro S, Picciocchi A, Coco C, Gasbarrini G, Gasbarrini A: Gene-expression profile of colorectal adenocarcinoma tissues identified by gene microarray analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):3651

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-expression profile of colorectal adenocarcinoma tissues identified by gene microarray analysis.
  • Aim of the study was to identify the gene expression of colorectal adenocarcinoma tissues compared to the normal mucosa.
  • METHODS: RNA was extracted from 3 samples of moderately differentiated sporadic rectal adenocarcinoma and 3 samples of normal rectal mucosa obtained from the same patients and hybridized against the human U133A array set.
  • Gene expression of tumoral tissues and normal samples was compared; a minimum of 3 times fold differential expression among the same genes in neoplastic and normal samples was considered as significant.
  • Real-time PCR (Roche, Manheim) using the same RNA was also performed on a pool of either up- or down-regulated randomly-selected genes to validate the results.
  • 537 genes were upregulated while 13 genes were downregulated in neoplastic tissues.
  • The up-regulated genes included angiogenic factors (VEGF, PD-ECGF, EGF), markers of proliferation (PCNA), tumoral markers (CEA, ACE), genes involved in chemotherapy activity (Farnesyl-transferase, Topoisomerase-1) and several other genes of unclear function.
  • CONCLUSIONS: Colorectal cancer tissues show a different gene expression compared to the normal mucosa.
  • This differential expression includes several known genes involved in cell growth, angiogenesis, transcription and proliferation as well as other genes of unclear activity, which have never previously been associated with cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014587.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Radonak J, Lakyová L, Toporcer T: [Uncommon rectal adenocarcinoma metastases]. Rozhl Chir; 2010 Aug;89(7):441-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uncommon rectal adenocarcinoma metastases].
  • Rectal cancer treatment has become multimodal as a result of significant advances in imaging diagnostic, in surgery technique of re section and in neo and adjuvant therapy.
  • The aim of the case report was to present a successfully treated adenocarcinoma recti and adenocarcinoma of hepatal flexurae with recidivistic metastasis and an extremely rare intergrowth of the metastasis into venous system.
  • A 61 year old patient underwent low resection of recti according to Dixon because of well differentiated adenocarcinoma with classification T3N0M0.
  • The patient was reoperated because of metastasis of adenocarcinoma in the abdominal wall (16 x 15 x 20 cm) after chemotherapy (FUL-5-fluorouracyl) and radiation dose of 50.4 Gy.
  • The metastasis of abdominal wall was extirpated after another cycle of adjuvant therapy of FUL+Leukovorin.
  • 26 months after the first operation, a new sessile polyp was found in the hepatal flexurae with histological finding of well differentiated adenocarcinoma.
  • Since lymphatic nodes were without metastasis, the patient was not indicated for chemotherapy.
  • [MeSH-major] Abdominal Neoplasms / secondary. Abdominal Wall. Adenocarcinoma / secondary. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20925261.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] slo
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


14. Blair S, Ellenhorn JD: Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology. Am Surg; 2000 Sep;66(9):817-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology.
  • Controversy still exists as to the optimal treatment of early-stage low rectal cancers.
  • We identified 20 patients from our prospective tumor registry database that underwent transanal resection of early rectal cancers between 1988 and 1998.
  • All T1 lesions were well or moderately well differentiated, and none had lymphovascular invasion.
  • Four patients had postoperative adjuvant therapy (radiation alone, two; radiation and chemotherapy, two) for close margins after they refused an abdominal perineal resection.
  • This series suggests that transanal excision is a safe and effective treatment for selected early low rectal cancers with favorable histology.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Chemotherapy, Adjuvant. Colon / surgery. Colostomy. Databases as Topic. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Perineum / surgery. Postoperative Complications / surgery. Prospective Studies. Radiotherapy, Adjuvant. Registries. Safety. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10993607.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Nozoe Y, Ogata Y, Miyagi Y, Nakagawa M, Matono K, Sasatomi T, Araki Y, Shirouzu K: [Efficacy of postoperative adjuvant chemotherapy for colorectal cancer]. Gan To Kagaku Ryoho; 2002 Jan;29(1):67-72
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of postoperative adjuvant chemotherapy for colorectal cancer].
  • We attempted postoperative adjuvant chemotherapy for stage II or III colorectal cancer.
  • To investigate the efficacy of the adjuvant chemotherapy, we retrospectively reviewed all 293 colorectal cancer patients who underwent curative resection between 1990 and 1996 in Kurume University Hospital.
  • The patients were divided into two groups according to whether or not they received postoperative adjuvant chemotherapy.
  • The disease-free survival rate in Group 1 was significantly higher than that in Group 2, but only for those with rectal cancer, with no significant difference for those with colon cancer.
  • Findings were similar between the two groups for those with stage II, stage IIIa, a low grade of lymphatic and venous invasion, and well-differentiated adenocarcinoma.
  • Postoperative adjuvant chemotherapy in colorectal cancer might reduce the risk of recurrence, particularly in cases of rectal cancer.
  • However, postoperative adjuvant chemotherapy was insufficient for those with highly advanced cancer or a biologically aggressive tumor.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Postoperative Care. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11816480.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Yoshitani S, Imaizumi H, Kuroda M, Yokoi M, Tanaka Y, Harada H, Kosaka T, Takashima S: [A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1867-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer].
  • The patient was a 64-year-old male who underwent an abdomino-perineal resection (D3) for advanced lower rectal carcinoma with a formulated vesicorectal abscess.
  • The tumor was a well-differentiated adenocarcinoma, type 2 in the Japanese Classification of Colorectal Carcinoma, and was measured 5.5x4.3 cm in size.
  • He received a postoperative chemotherapy with oral UFT-E (400 mg/day) for 1 year.
  • After 2 years from the surgery, the patient developed a perineal pain, and pelvic CT scans revealed a 4 cm mass anterior to the sacrum.
  • Radiotherapy was given to the pelvic region at a total dose of 70 Gy (Given 2 Gy each x 35 fragments).
  • Chemotherapy with CDDP and 5-FU was administered via the right internal iliac artery followed by administration of 5'-DFUR (600 mg/day).
  • After that regimen, a recurrence of the pelvic tumor caused an increase in pain, and the patient developed renal failure.
  • He died after 4 years and 10 months from the initial detection of recurrence.
  • This report presents a case of local recurrence of advanced rectal carcinoma, in which we were able to achieve a long-term survival and improvement in QOL by an intensive multidisciplinary therapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / therapy. Rectal Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Floxuridine / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553742.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


17. Kumazawa S, Murata Y, Ishita T, Nakamura S, Tamura N, Oikawa Y, Kubo Y, Kurata N, Yagi K, Hattori S, Bando M, Mori M, Matsumoto K, Sato Y, Machinami R: [A case of advanced rectal cancer with multiple liver metastases successfully treated by perioperative administration of UFT and oral leucovorin]. Gan To Kagaku Ryoho; 2010 Sep;37(9):1817-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced rectal cancer with multiple liver metastases successfully treated by perioperative administration of UFT and oral leucovorin].
  • The patient was a sixty-five-year-old man who had an advanced rectal cancer (Ra, type 2) with liver metastases.
  • The pathological finding was moderately-differentiated adenocarcinoma.
  • He was treated with 5-FU via the hepatic artery, but the therapy failed due to catheter infection after 3 postoperative months.
  • Then, he received general 5-FU/l-LV therapy intravenously from 3 to 8 months after the operation, and oral UFT/LV (Uzel®) from 9 to 22 months.
  • Next, we switched to single UFT therapy at 23 months because CT findings showed remarkable calcification in the liver metastases.
  • We switched the chemotherapy again to UFT/Uzel and mFOLFOX6, but decided to perform hepatectomy of S6/7 at 39 months since it proved ineffective.
  • Now, NC in the liver is continued 67 months after the first operation, and the patient is doing well.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leucovorin / therapeutic use. Liver Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Combined Modality Therapy. Hepatectomy. Humans. Male. Neoplasm Staging. Tegafur / administration & dosage. Tegafur / therapeutic use. Tomography, X-Ray Computed. Uracil / administration & dosage. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20841955.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin; 1-UFT protocol
  •  go-up   go-down


18. Katsumata K, Ichimiya H, Wakana Y, Okada K, Kato K, Aoki T: [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy]. Gan To Kagaku Ryoho; 2004 Apr;31(4):623-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
  • We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin.
  • Case 1 was a 40-year-old man with rectal carcinoma (moderately differentiated adenocarcinoma; se, n1, p1, H0, stage IV).
  • At course 3, the liver metastasis showed partial response and, during the 18 months after the 7th course, his peritoneal dissemination and other lesions were well controlled.
  • As of 30 months post-treatment the patient was alive.
  • Case 2 was a 60-year-old man with rectal carcinoma (well differentiated adenocarcinoma; ss, n1, p0, H1, stage IV).
  • Adverse drug reactions in both patients were controlled on an outpatient basis.
  • While in the past liver metastasis has been treated by hepatic arterial infusion chemotherapy, a combination therapy with fluorouracil and l-Leucovorin can be used on an outpatient basis and results in a favorable response.
  • This suggests that this combination therapy has clinical significance.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Drug Administration Schedule. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Male. Middle Aged. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114713.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Nishimura R, Teramoto N, Tanada M, Kurita A, Mogami H: Inflammatory pseudotumor of the liver associated with malignant disease: report of two cases and a review of the literature. Virchows Arch; 2005 Sep;447(3):660-4
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first patient was a 63-year-old woman who underwent distal gastrectomy and partial hepatectomy under a diagnosis of stomach cancer with liver metastasis.
  • The second patient was a 66-year-old man who had undergone surgery for rectal cancer 6 years previously and underwent partial hepatectomy under a diagnosis of metastasis of rectal cancer to the liver.
  • The gastric cancer was a papillary adenocarcinoma limited to the mucosa, and the rectal cancer was a moderately differentiated adenocarcinoma limited to the subserosa.
  • The cut surface showed that both masses were well circumscribed and divided into lobules by fibrous tissue.
  • Obliterating phlebitis suggesting infection via the portal vein was seen in the adjacent liver tissue in both cases.
  • According to previous cases reported in the literature, there are three types of cancers associated with hepatic IPT: gastrointestinal tract cancer, biliary tract cancer, and cancers that need strong systemic chemotherapy.
  • The underlying cancer types of IPT of the liver are almost similar to those associated with pyogenic liver abscesses suggesting the etiological correlation between IPT and abscesses of the liver.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Granuloma, Plasma Cell / complications. Granuloma, Plasma Cell / pathology. Liver Diseases / pathology
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Liver Abscess / complications. Liver Abscess / pathology. Male. Middle Aged. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1993 Dec;128(12):1358-64; discussion 1364 [8250709.001]
  • [Cites] Intern Med. 1998 Jun;37(6):542-5 [9678690.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):242-5 [9517733.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):231-8 [8382011.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):747-53 [8651355.001]
  • [Cites] Surg Today. 2000;30(6):530-3 [10883465.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):761-8 [11395553.001]
  • [Cites] Am J Gastroenterol. 1991 Feb;86(2):238-40 [1992642.001]
  • [Cites] AJR Am J Roentgenol. 1999 Oct;173(4):1049-54 [10511176.001]
  • [Cites] J Gastroenterol. 2000;35(4):304-9 [10777162.001]
  • [Cites] Pathol Res Pract. 1997;193(7):519-25; discussion 526 [9342759.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1583-90 [2155699.001]
  • [Cites] J Gastroenterol. 1995 Jun;30(3):408-12 [7647910.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):721-31 [11395549.001]
  • [Cites] Eur J Pediatr Surg. 1999 Oct;9(5):343-6 [10584199.001]
  • [Cites] Clin Diagn Lab Immunol. 2004 Jan;11(1):123-30 [14715558.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):172-5 [1310343.001]
  • [Cites] Eur Radiol. 2002 Oct;12(10):2484-7 [12271389.001]
  • (PMID = 15968548.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


20. Kravarusic D, Feigin E, Dlugy E, Steinberg R, Baazov A, Erez I, Lazar L, Kapuller V, Grunspan M, Ash S, Freud E: Colorectal carcinoma in childhood: a retrospective multicenter study. J Pediatr Gastroenterol Nutr; 2007 Feb;44(2):209-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this multicenter study was to document the clinical profile, treatment and prognosis of colorectal carcinoma in children in Israel.
  • PATIENTS AND METHODS: The clinical, laboratory, therapeutic, and prognostic parameters of all 7 children from 4 medical centers in Israel who were diagnosed with colorectal carcinoma over a 25-y period were reviewed.
  • RESULTS: Patients presented with rectal bleeding (4 of 7), abdominal pain (2 of 7), and abdominal distension (2 of 7).
  • Average time to diagnosis was 6 months.
  • Six patients underwent surgery (1 refused), and 5 received chemotherapy.
  • Histopathological studies showed poorly differentiated mucinous adenocarcinoma, signet-ring type, in 4 cases, moderately differentiated adenocarcinoma in 2, and well-differentiated carcinoma in 1.
  • Heightened physician awareness of the possibility of this disease in children, with special attention to adolescents with predisposing factors and rectal bleeding, could help to improve outcome.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child, Preschool. Colectomy. Female. Humans. Israel. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255833.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Balta Z, Sauerbruch T, Hirner A, Büttner R, Fischer HP: [Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small-cell hepatic carcinoma: case reports and review of the literature]. Pathologe; 2008 Feb;29(1):53-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While primary hepatic carcinoid tumors (PHCT) are well-differentiated tumors, primary hepatic small-cell carcinomas (PHSCC) represent the poorly differentiated end of the spectrum of neuroendocrine carcinomas.
  • Within this time, the tumor relapsed 4 times with unchanged histology and immunohistochemistry features.
  • After neoadjuvant cytostatic treatment the carcinoma was completely extirpated and 18 months after treatment the patient is healthy.PHCT and PHSCC have to be clearly separated from hepatocellular and cholangiocellular carcinomas.
  • Surgical resection is the treatment of choice.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoid Tumor / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carboplatin / administration & dosage. Cell Differentiation. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Rectal Neoplasms / pathology. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Med. 1993 May-Jun;11(3):102-6 [8372237.001]
  • [Cites] Br J Surg. 1989 Mar;76(3):248-9 [2655808.001]
  • [Cites] Dig Dis Sci. 2003 Aug;48(8):1665-7 [12924666.001]
  • [Cites] Clin Nucl Med. 2005 Jul;30(7):530-1 [15965342.001]
  • [Cites] Dtsch Med Wochenschr. 1989 Apr 21;114(16):623-7 [2707129.001]
  • [Cites] Radiat Med. 1995 Jul-Aug;13(4):183-5 [8539446.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2547-50 [10522038.001]
  • [Cites] Surgery. 1992 Dec;112(6):1039-46; discussion 1046-7 [1455307.001]
  • [Cites] J Chin Med Assoc. 2003 Apr;66(4):247-51 [12854878.001]
  • [Cites] Ultrastruct Pathol. 1986;10(4):331-6 [3739044.001]
  • [Cites] Jpn J Clin Oncol. 1999 May;29(5):252-5 [10379337.001]
  • [Cites] Abdom Imaging. 2002 May-Jun;27(3):325-8 [12173364.001]
  • [Cites] Ultrastruct Pathol. 1992 Nov-Dec;16(6):667-72 [1448886.001]
  • [Cites] Med Sci Monit. 2001 Jul-Aug;7(4):746-50 [11433205.001]
  • [Cites] Hepatol Res. 2002 Apr;22(4):313-321 [11929717.001]
  • [Cites] J Comput Assist Tomogr. 1992 Jan-Feb;16(1):99-102 [1729316.001]
  • [Cites] Digestion. 1999 Mar-Apr;60(2):110-6 [10095151.001]
  • [Cites] Abdom Imaging. 2005 May-Jun;30(3):281-5 [15785908.001]
  • [Cites] Am J Clin Pathol. 1988 Apr;89(4):561-4 [3354510.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):210-9 [14745329.001]
  • [Cites] J Comput Tomogr. 1986 Oct;10 (4):313-7 [3780258.001]
  • [Cites] Surgery. 1998 Dec;124(6):1145-52 [9854596.001]
  • [Cites] Pathol Int. 2001 Nov;51(11):874-8 [11844054.001]
  • [Cites] Virchows Arch. 2006 May;448(5):655-8 [16541281.001]
  • [Cites] J Gastroenterol. 1999 Feb;34(1):123-7 [10204622.001]
  • [Cites] Korean J Hepatol. 2005 Sep;11(3):289-92 [16177556.001]
  • [Cites] Radiat Med. 1998 Sep-Oct;16(5):371-3 [9862161.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1119-24 [12201876.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2660-5 [8453589.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1218-20 [16001665.001]
  • [Cites] Surg Today. 2003;33(3):214-8 [12658390.001]
  • [Cites] Am J Surg Pathol. 1992 Aug;16(8):802-7 [1497121.001]
  • [Cites] Histopathology. 1996 Nov;29(5):449-53 [8951490.001]
  • [Cites] Med Princ Pract. 2005 Jul-Aug;14 (4):288-91 [15961944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8078-83 [12048252.001]
  • [Cites] Pathol Int. 1998 Jun;48(6):481-5 [9702863.001]
  • [Cites] J Korean Med Sci. 1998 Jun;13(3):317-20 [9681813.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1171-5 [14654473.001]
  • [Cites] Pathol Oncol Res. 1999;5(1):67-9 [10079384.001]
  • [Cites] Surgery. 1988 Dec;104(6):1080-9 [3194834.001]
  • [Cites] Int J Gastrointest Cancer. 2005;35(2):147-51 [15879630.001]
  • [Cites] Acta Chir Belg. 1999 Dec;99(6):299-302 [10674133.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):218-21 [8667631.001]
  • [Cites] Cancer. 1990 Mar 1;65(5):1211-8 [2302669.001]
  • [Cites] Am J Clin Pathol. 1991 Feb;95(2):172-5 [1704179.001]
  • [Cites] J Clin Gastroenterol. 1996 Jul;23(1):60-2 [8835904.001]
  • [Cites] J Clin Ultrasound. 2005 Jul-Aug;33(6):302-4 [16134160.001]
  • [Cites] Am J Gastroenterol. 1993 Jun;88(6):958-61 [8389095.001]
  • [Cites] Br J Radiol. 1999 Feb;72(854):207-9 [10365076.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1146-51 [7194135.001]
  • [Cites] Intern Med. 2005 Sep;44(9):958-62 [16258211.001]
  • [Cites] Acta Pathol Jpn. 1993 Dec;43(12):783-9 [8109257.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2227-30 [11344231.001]
  • [Cites] Jpn J Clin Oncol. 1992 Feb;22(1):54-9 [1374135.001]
  • [Cites] Pathol Int. 1999 Apr;49(4):318-24 [10365851.001]
  • [Cites] Hepatogastroenterology. 2000 Mar-Apr;47(32):528-30 [10791229.001]
  • (PMID = 18210116.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down






Advertisement